brexucabtagene mantle cell
Selected indexed studies
- Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. (Drugs Today (Barc), 2022) [PMID:35670706]
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. (J Clin Oncol, 2023) [PMID:35658525]
- Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. (Expert Opin Biol Ther, 2021) [PMID:33566715]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. (2023) pubmed
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. (2023) pubmed
- Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. (2022) pubmed
- Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. (2022) pubmed
- Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia. (2023) pubmed
- PMID:40737466 (2021) pubmed
- Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. (2021) pubmed
- Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. (2025) pubmed
- Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis. (2024) pubmed
- Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma. (2023) pubmed